SELLAS Life Sciences Group shares surged as much as 233% during Tuesday’s trading after the biotechnology company announced positive results from a late-stage clinical trial of its experimental cancer vaccine, galinpepimut-S. The treatment demonstrated a statistically significant survival benefit in patients with acute myeloid leukemia (AML), an aggressive blood cancer, triggering a sharp rally in the company’s stock and making it one of the session’s biggest market gainers.

The Phase 3 REGAL trial met its primary endpoint of overall survival, with the experimental immunotherapy reducing the risk of death by 41% compared with the best available treatment. Patients receiving galinpepimut-S recorded median overall survival of 24 months, compared with 14.7 months in the control group. The results have strengthened expectations around the drug’s potential regulatory pathway, although it remains investigational and has not yet received approval.

SELLAS Life Sciences Stock Surges 233% After Cancer Vaccine Results

Shares of SELLAS Life Sciences Group (NASDAQ: SLS) jumped dramatically after the company announced positive topline data from its pivotal Phase 3 REGAL trial on November 17, 2026.

The stock gained approximately 156% by the close of Tuesday’s session, while the shares briefly surged as much as 233% intraday, reflecting strong investor reaction to the clinical results.

The rally marked the company’s biggest single-day gain since 2020 and reflected growing optimism that its experimental immunotherapy could become a potential treatment option for patients with limited alternatives.

The clinical results were particularly significant because the trial evaluated patients with AML who had experienced multiple treatment stages and were unable to undergo stem-cell transplantation.

Cancer Vaccine Reduces Risk of Death by 41%

SELLAS announced that its investigational cancer vaccine galinpepimut-S, also known as GPS, met the primary endpoint of overall survival in the REGAL trial.

The treatment demonstrated a 41% reduction in the risk of death compared with the investigator’s choice of best available treatment.

REGAL Phase 3 Trial ResultsGPS VaccineControl Group
Median overall survival24.0 months14.7 months
Hazard ratio0.59Reference
Reduction in risk of death41%—
Statistical significancep = 0.035—

The hazard ratio of 0.59 indicates a lower rate of death in the GPS treatment group compared with the control group over the study period.

The results were statistically significant, with a two-sided p-value of 0.035. However, the results represent findings from a clinical trial and do not establish that the vaccine will work for every patient or receive regulatory approval.

What Is Galinpepimut-S and How Does It Work?

Galinpepimut-S is an investigational immunotherapeutic cancer vaccine designed to activate the immune system against cancer cells expressing a protein called Wilms Tumor 1, or WT1.

WT1 is expressed in several types of cancers, including acute myeloid leukemia. The vaccine uses WT1-derived peptides to stimulate immune responses involving T cells, which may help the body recognise and attack cancer cells carrying the target protein.

Unlike conventional treatments that directly kill cancer cells, immunotherapies aim to strengthen or direct the body’s own immune response against cancer.

GPS is an off-the-shelf vaccine, meaning it is not individually manufactured for each patient. This could potentially make its administration more practical than certain personalised cell-based cancer treatments, depending on the eventual treatment protocol.

Phase 3 REGAL Trial Targeted High-Risk AML Patients

The REGAL study evaluated galinpepimut-S as maintenance monotherapy in patients with acute myeloid leukemia who achieved a second or later remission following salvage therapy.

The trial focused on patients who were ineligible for or unable to undergo allogeneic stem-cell transplantation, leaving them with limited treatment options.

AML is an aggressive cancer affecting the blood and bone marrow. Although some patients achieve remission following initial treatment, the disease can relapse, creating difficult treatment challenges.

The survival benefit reported by SELLAS is therefore important because the study population represents patients with significant unmet medical needs.

The topline analysis was conducted after the trial reached its prespecified threshold of 80 deaths, in accordance with the study’s statistical analysis plan.

Cancer Vaccine Was Generally Well Tolerated

Alongside the efficacy results, SELLAS reported that galinpepimut-S was generally well tolerated, with a safety profile consistent with previous clinical experience.

The company reported no new safety signals in the topline results. Treatment-related adverse events were predominantly mild to moderate, with injection-site reactions among the commonly reported effects.

Safety is an important consideration for maintenance treatment, particularly among patients who have already undergone intensive chemotherapy and multiple treatment stages.

The full safety analysis and additional clinical data are expected to provide a more comprehensive picture of the treatment’s risk-benefit profile.

SELLAS Plans FDA Discussions and Potential 2027 Filing

Following the successful Phase 3 results, SELLAS plans to meet with the U.S. Food and Drug Administration to discuss a potential accelerated filing strategy for galinpepimut-S.

The company is advancing preparations for a Biologics License Application, or BLA, submission in the first half of 2027.

The next regulatory steps could determine whether the vaccine qualifies for an accelerated development or review pathway and what additional information the FDA may require before considering approval.

SELLAS is also conducting additional analyses of secondary endpoints and other prespecified study data. The company expects to present more detailed results at an upcoming medical conference and submit the findings for publication in a peer-reviewed journal.

Why Investors Are Betting on SELLAS Life Sciences

The clinical results represent a major potential milestone for SELLAS, a biotechnology company whose valuation is heavily influenced by the development and commercial prospects of its pipeline treatments.

Positive Phase 3 results can significantly change expectations around a drug’s commercial potential, particularly when the treatment targets a disease with limited therapeutic options.

Investors are now evaluating several factors:

  • The potential regulatory pathway for galinpepimut-S.
  • The possibility of FDA approval and future commercialisation.
  • The size of the eligible AML patient population.
  • The treatment’s safety and efficacy profile.
  • SELLAS’s financing requirements and ability to fund further development.

However, biotechnology stocks can experience extreme volatility following clinical trial announcements. A sharp rally does not guarantee regulatory approval, commercial success or sustained share-price gains.

SELLAS Announces $150 Million Stock Offering After Rally

Following the dramatic increase in its share price, SELLAS also announced a proposed $150 million stock offering, adding another major development for investors.

The capital raise could provide the company with additional funding to advance its clinical pipeline, prepare for regulatory activities and support operations.

However, issuing additional shares can dilute existing shareholders, depending on the offering structure, pricing and number of shares issued.

The timing of a financing announcement following a major rally is particularly important because investors must weigh the company’s funding needs against the potential dilution and the valuation implied by the share price.

The Bigger Picture

The SELLAS rally highlights how clinical trial results can dramatically reshape the valuation of biotechnology companies. A successful late-stage study can move an experimental treatment closer to regulatory review, creating expectations around future revenue and commercial opportunities.

Cancer immunotherapy remains an important area of pharmaceutical research, with companies exploring ways to use the immune system to recognise and eliminate cancer cells. However, the industry is also characterised by significant clinical, regulatory and financial risks.

For SELLAS, the REGAL trial results represent a major clinical milestone. The next challenge will be converting the survival data into a viable regulatory and commercial pathway.

Looking Ahead

SELLAS is preparing for discussions with the FDA while advancing its planned BLA submission for galinpepimut-S in the first half of 2027. Further clinical analyses, conference presentations and regulatory feedback will be critical in determining the next stage of development. The company will also need to manage financing and operational costs as it moves toward potential commercialisation.

The stock’s extraordinary rally reflects investor optimism about the vaccine’s clinical potential, but its future performance will depend on regulatory progress, additional data, financing decisions and market expectations. The Phase 3 results have put SELLAS firmly on investors’ radar, but the path from clinical success to an approved cancer treatment remains a complex process.

Get the day’s top stories in your inbox

One concise email. No spam, unsubscribe anytime.